Milena Doroszko
Overview
Explore the profile of Milena Doroszko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mariniello K, Pittaway J, Altieri B, Borges K, Hadjidemetriou I, Ribeiro C, et al.
Cancer Commun (Lond)
. 2025 Mar;
PMID: 40035383
No abstract available.
2.
Mariniello K, Pittaway J, Altieri B, Borges K, Hadjidemetriou I, Ribeiro C, et al.
bioRxiv
. 2024 Sep;
PMID: 39229217
Disruption of processes involved in tissue development and homeostatic self-renewal is increasingly implicated in cancer initiation, progression, and recurrence. The adrenal cortex is a dynamic tissue that undergoes life-long turnover....
3.
Kerzeli I, Lord M, Doroszko M, Elgendy R, Chourlia A, Stepanek I, et al.
PLoS One
. 2024 May;
19(5):e0304890.
PMID: 38820327
[This corrects the article DOI: 10.1371/journal.pone.0253178.].
4.
Patyra K, Lof C, Jaeschke H, Undeutsch H, Zheng H, Tyystjarvi S, et al.
Thyroid
. 2022 Jan;
32(4):459-471.
PMID: 35044245
The human adrenal cortex undergoes several rapid remodeling steps during its lifetime. In rodents, similar remodeling occurs postnatally in the "X-zone" layer through unknown mechanisms. Furthermore, little is known regarding...
5.
Larsson I, Dalmo E, Elgendy R, Niklasson M, Doroszko M, Segerman A, et al.
Mol Syst Biol
. 2021 Sep;
17(9):e10105.
PMID: 34528760
Tumor cell heterogeneity is a crucial characteristic of malignant brain tumors and underpins phenomena such as therapy resistance and tumor recurrence. Advances in single-cell analysis have enabled the delineation of...
6.
Kerzeli I, Lord M, Doroszko M, Elgendy R, Chourlia A, Stepanek I, et al.
PLoS One
. 2021 Jul;
16(7):e0253178.
PMID: 34232958
Bladder cancer, one of the most prevalent malignancies worldwide, remains hard to classify due to a staggering molecular complexity. Despite a plethora of diagnostic tools and therapies, it is hard...
7.
Oduwole O, Poliandri A, Okolo A, Rawson P, Doroszko M, Chrusciel M, et al.
FASEB J
. 2021 Mar;
35(4):e21464.
PMID: 33724574
Chemical castration in prostate cancer can be achieved with gonadotropin-releasing hormone (GnRH) agonists or antagonists. Their effects differ by the initial flare of gonadotropin and testosterone secretion with agonists and...
8.
Merisaari J, Denisova O, Doroszko M, Le Joncour V, Johansson P, Leenders W, et al.
Brain Commun
. 2020 Sep;
2(1):fcaa002.
PMID: 32954276
Glioblastoma is a fatal disease in which most targeted therapies have clinically failed. However, pharmacological reactivation of tumour suppressors has not been thoroughly studied as yet as a glioblastoma therapeutic...
9.
Veikkolainen V, Ali N, Doroszko M, Kiviniemi A, Miinalainen I, Ohlsson C, et al.
Hum Mol Genet
. 2020 Jul;
29(17):2813-2830.
PMID: 32716031
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders leading to infertility in women affecting reproductive, endocrine and metabolic systems. Recent genomewide association studies on PCOS cohorts...
10.
Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, et al.
Cell Rep
. 2020 Jul;
32(2):107897.
PMID: 32668248
Glioblastoma (GBM) is a malignant brain tumor with few therapeutic options. The disease presents with a complex spectrum of genomic aberrations, but the pharmacological consequences of these aberrations are partly...